查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1564984

分子腫瘤診斷的全球市場

Oncology Molecular Diagnostics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球分子腫瘤診斷市場（美國）預計將達到 108 億美元

分子腫瘤診斷的全球市場預計到 2023 年將達到 52 億美元，預計在 2023 年至 2030 年分析期間將以 11.1% 的複合年成長率成長，並在 2030 年達到 108 億美元。乳癌是本報告分析的細分市場之一，預計複合年成長率為 9.0%，到分析期結束時將達到 29 億美元。在分析期間，大腸直腸癌領域的複合年成長率估計為 14.6%。

美國市場預計14億美元，中國預計複合年成長率14.2%

預計 2023 年美國分子腫瘤診斷市場規模將達 14 億美元。中國作為世界第二大經濟體，預計2030年市場規模將達25億美元，2023-2030年分析期間複合年成長率為14.2%。其他值得注意的區域市場包括日本和加拿大，在分析期間預計複合年成長率分別為 7.7% 和 9.0%。在歐洲，德國的複合年成長率預計約為 8.5%。

全球腫瘤分子診斷市場趨勢及促進因素總結

什麼是分子腫瘤診斷？

分子腫瘤診斷是指分析癌細胞基因突變、生物標記和其他分子特徵的分子生物學技術。該方法透過在分子層面上識別特定的突變和異常，實現早期準確的癌症檢測、預後預測和個人化治療計劃。分子診斷對於精準腫瘤學至關重要，精準腫瘤學可以根據個體的遺傳特徵客製化治療方法，並提供更有效、更有針對性的癌症治療。聚合酵素鏈鎖反應（PCR）、次世代定序（NGS）和液態切片等技術常用於分子腫瘤診斷，使腫瘤學家能夠分析固體癌、血液癌症和轉移性疾病的基因。隨著癌症治療轉向更個人化的分子方法，分子診斷的角色對於改善患者的治療結果和生存變得至關重要。

科技創新如何加速分子診斷在腫瘤學的應用？

技術進步在擴大分子腫瘤診斷的範圍和能力方面發揮著重要作用。次世代定序(NGS) 徹底改變了這個領域，允許在一次測試中同時分析多個基因和基因突變。這項創新技術能夠實現全面的基因組分析，這對於識別可操作的突變以指南標靶治療決策至關重要。液態切片也是一項新興的尖端最尖端科技，它提供了一種非侵入性的方法來檢測血液中循環腫瘤 DNA (ctDNA) 的癌症突變。這種方法對於監測治療效果和即時檢測復發特別有用。使用生物資訊學和人工智慧進行資料分析的進步也提高了分子診斷的準確性和速度，使解釋複雜的基因組資料變得更加容易。這些技術創新使分子診斷變得更快、更容易，並且在常規腫瘤治療中變得越來越重要。

為什麼分子診斷對於精準腫瘤學和患者治療結果至關重要？

分子診斷是不斷發展的精準腫瘤學領域的核心，該領域根據個別腫瘤的基因組成進行個人化癌症治療。透過識別特定的突變和生物標記物，分子診斷使腫瘤學家能夠選擇直接抑制導致癌症的基因變化的標靶治療，從而提高治療效果並最大限度地減少副作用。例如，具有 EGFR、ALK 和 BRCA 等基因突變的患者可以根據其分子特徵採用更有效的特定標靶治療或免疫療法進行治療。此外，分子診斷可以早期發現癌症，增加介入和治療成功的可能性。除了診斷之外，這些測試還用於監測微量殘存疾病(MRD)、追蹤治療反應、檢測癌症復發的早期跡象，並最終提高患者的生存率和生活品質。

推動分子腫瘤診斷市場成長的因素有哪些？

有幾個因素正在推動分子腫瘤學診斷市場的成長，最顯著的是癌症發生率的上升和對精準醫療的需求不斷成長。隨著全球癌症發生率的上升，醫療保健提供者越來越依賴分子診斷來指南治療決策，導致對先進檢測解決方案的需求激增。次世代定序(NGS)、液態切片和人工智慧資料分析等技術的進步使這些診斷更加準確和方便。向個人化癌症治療（例如標靶治療和免疫療法）的轉變也是一個主要驅動力，分子診斷對於識別將從這些治療中受益的患者至關重要。此外，監管機構對伴同性診斷（幫助患者與適當治療方法相符的測試）的核准不斷增加也推動了市場擴張。擴大關注癌症的早期檢測和監測以及增加研發投資預計將在未來幾年維持該市場的強勁成長。

受訪企業範例（共12家）

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics（Schweiz）AG
  • Siemens Healthineers
  • Sysmex Corporation

目錄

第1章調查方法

第 2 章執行摘要

  • 市場概況
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP13704

Global Oncology Molecular Diagnostics Market to Reach US$10.8 Billion by 2030

The global market for Oncology Molecular Diagnostics estimated at US$5.2 Billion in the year 2023, is expected to reach US$10.8 Billion by 2030, growing at a CAGR of 11.1% over the analysis period 2023-2030. Breast Cancer, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Colorectal Cancer segment is estimated at 14.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 14.2% CAGR

The Oncology Molecular Diagnostics market in the U.S. is estimated at US$1.4 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 14.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.7% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.5% CAGR.

Global Oncology Molecular Diagnostics Market – Key Trends & Drivers Summarized

What Is Oncology Molecular Diagnostics and Why Is It Transforming Cancer Care?

Oncology molecular diagnostics refers to the use of molecular biology techniques to analyze genetic mutations, biomarkers, and other molecular characteristics in cancer cells. This approach enables early and accurate cancer detection, prognosis, and personalized treatment plans by identifying specific mutations or abnormalities at the molecular level. Molecular diagnostics are essential for precision oncology, where therapies are tailored to an individual's genetic profile, providing more effective and targeted cancer treatment. Techniques such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and liquid biopsy are commonly employed in oncology molecular diagnostics, allowing oncologists to detect genetic variations in solid tumors, hematological cancers, and metastatic diseases. As cancer treatment moves towards more personalized and molecularly driven approaches, the role of molecular diagnostics has become indispensable in improving patient outcomes and survival rates.

How Are Technological Innovations Accelerating the Adoption of Molecular Diagnostics in Oncology?

Technological advancements have played a crucial role in expanding the scope and capabilities of oncology molecular diagnostics. Next-generation sequencing (NGS) has revolutionized the field, enabling the simultaneous analysis of multiple genes and genetic mutations in a single test. This innovation allows for comprehensive genomic profiling, which is essential for identifying actionable mutations that can guide targeted therapy decisions. Liquid biopsy is another cutting-edge technology that is gaining traction, offering a non-invasive method for detecting cancer mutations from circulating tumor DNA (ctDNA) in the blood. This approach is particularly valuable in monitoring treatment response and detecting relapse in real time. Advances in bioinformatics and AI-powered data analysis are also enhancing the accuracy and speed of molecular diagnostics, making it easier to interpret complex genomic data. These technological innovations are making molecular diagnostics faster, more accessible, and increasingly vital in routine oncology care.

Why Is Molecular Diagnostics Crucial for Precision Oncology and Patient Outcomes?

Molecular diagnostics is central to the growing field of precision oncology, where cancer treatments are personalized based on the genetic makeup of an individual’s tumor. By identifying specific mutations and biomarkers, molecular diagnostics allow oncologists to select targeted therapies that directly interfere with the cancer-driving genetic alterations, thereby improving the effectiveness of treatment and minimizing side effects. For example, patients with mutations in genes like EGFR, ALK, or BRCA can be treated with specific targeted therapies or immunotherapies that are more likely to work based on their molecular profile. Additionally, molecular diagnostics enable early cancer detection, increasing the chances of successful intervention and treatment. Beyond diagnosis, these tests are used for monitoring minimal residual disease (MRD), tracking response to therapies, and detecting early signs of cancer recurrence, ultimately improving patient survival rates and quality of life.

What Factors Are Driving Growth in the Oncology Molecular Diagnostics Market?

The growth in the oncology molecular diagnostics market is driven by several factors, most notably the rising incidence of cancer and the increasing demand for precision medicine. As the global cancer burden grows, healthcare providers are increasingly relying on molecular diagnostics to guide treatment decisions, leading to a surge in demand for advanced testing solutions. Technological advancements, including next-generation sequencing (NGS), liquid biopsy, and AI-driven data analysis, are making these diagnostics more precise and accessible. The shift towards personalized cancer therapies, such as targeted therapies and immunotherapies, is another major growth driver, as molecular diagnostics are essential for identifying patients who will benefit from these treatments. Moreover, increased regulatory approvals for companion diagnostics—tests that help match patients with the right therapies—are fueling market expansion. The growing focus on early detection and monitoring of cancer, alongside increasing investments in research and development, is expected to sustain robust growth in this market over the coming years.

Select Competitors (Total 12 Featured) -

  • Abbott Laboratories
  • Bayer Healthcare AG
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • Cepheid, Inc.
  • Danaher Corporation
  • Hologic, Inc.
  • Leica Biosystems Inc.
  • Qiagen NV
  • Roche Diagnostics (Schweiz) AG
  • Siemens Healthineers
  • Sysmex Corporation

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Oncology Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Cancer Worldwide Drives Demand for Advanced Oncology Molecular Diagnostics for Early Detection
    • Increased Focus on Personalized and Precision Medicine Expands Addressable Market for Oncology Molecular Diagnostics
    • Advancements in Liquid Biopsy Technology Propel Growth of Non-Invasive Molecular Diagnostics in Oncology
    • The Integration of Next-Generation Sequencing (NGS) in Oncology Diagnostics Spurs Adoption in Precision Oncology
    • Growing Demand for Companion Diagnostics Strengthens the Business Case for Oncology Molecular Diagnostics Solutions
    • Rising Use of Biomarker-Based Diagnostics Accelerates Demand for Molecular Tests in Targeted Cancer Therapies
    • Increasing Application of Molecular Diagnostics in Immuno-Oncology Expands Market Growth Opportunities
    • Technological Advancements in Point-of-Care Diagnostics Drive the Adoption of Molecular Oncology Solutions in Clinical Settings
    • Shift Toward Liquid Biopsies for Cancer Monitoring Generates Demand for Oncology Molecular Diagnostics
    • Growing Demand for Multi-Gene Panel Testing in Cancer Diagnostics Strengthens Business Case for Advanced Molecular Solutions
    • Rising Awareness of Genetic Predisposition and Hereditary Cancer Testing Spurs Growth in Molecular Oncology Diagnostics
    • Increasing Use of AI and Machine Learning in Molecular Diagnostics Expands the Market for Predictive Oncology Solutions
    • Rise of Consumer Genomics and Direct-to-Consumer Genetic Testing Drives Demand for Oncology Molecular Diagnostics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oncology Molecular Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oncology Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Liver Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Liver Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Instruments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Instruments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Segments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Other Segments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • JAPAN
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • CHINA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • EUROPE
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Oncology Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • FRANCE
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • GERMANY
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • INDIA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Oncology Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Oncology Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030
  • AFRICA
    • Oncology Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Oncology Molecular Diagnostics by Disease Type - Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Oncology Molecular Diagnostics by Disease Type - Percentage Breakdown of Value Sales for Breast Cancer, Colorectal Cancer, Prostate Cancer, Liver Cancer and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Oncology Molecular Diagnostics by Segment - Reagents, Instruments and Other Segments Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Oncology Molecular Diagnostics by Segment - Percentage Breakdown of Value Sales for Reagents, Instruments and Other Segments for the Years 2014, 2024 & 2030

IV. COMPETITION